ImmuneOncia Therapeutics Inc.

ImmuneOncia Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in immuno-oncology. Founded in 2016 as a joint venture between South Korea’s Yuhan Corporation and the U.S.-based Sorrento Therapeutics, the company is dedicated to developing novel immunotherapies for cancer patients worldwide. Its portfolio centers around antibody-based treatments, with a key focus on immune checkpoint inhibitors. Among its lead programs is IMC-001, a PD-L1 inhibitor recognized as the first domestically developed drug of its class to achieve investigational new drug status in Korea, now advancing through late-stage clinical trials. Additionally, ImmuneOncia is expanding its pipeline with monoclonal and bispecific antibodies targeting various immune pathways, such as anti-CD47 and next-generation bispecifics like PD-L1×CD47 and PD-L1×TIGIT. The company’s research and development efforts aim to address unmet needs in oncology, supporting Korea's innovation drive in the global biopharmaceutical sector. Backed by strong institutional support and operating from Yongin, South Korea, ImmuneOncia positions itself as a significant player in advancing cancer immunotherapy within Asia and beyond.